It is called a specific therapy as it particularly targets the CD38  which can be overexpressed around the multiple myeloma cells. Daratumumab is from a class of medicines called CD38 monoclonal antibodies. Daratumumab-mediated optimistic indirect antiglobulin take a look at may perhaps persist for as much as 6 months after the final daratumumab